CGP60474, a novel MITD1-targeted inhibitor for bladder cancer progression via CDK4/cyclin D1 pathway modulation

Abstract Targeted therapy holds promise for advanced bladder cancer, but its development is limited by a lack of therapeutic targets. Here, we show that MITD1 is elevated in bladder cancer and associated with poor patient prognosis. We find that MITD1 drives cancer progression by interacting with the CDK4/cyclin D1 complex to regulate the cell cycle. Genetic deletion of MITD1 inhibits tumor growth, confirming its key role. Furthermore, we identify the small molecule CGP60474 as an MITD1-targeted inhibitor. CGP60474 demonstrates potent anti-tumor activity in preclinical models and exhibits a favorable safety profile. Our study establishes MITD1 as a therapeutic target and nominates CGP60474 as a candidate for developing new bladder cancer treatments.